Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menveo one-dose versus two-dose immunogenicity study in healthy children aged 2 to 10 years
2011-004421-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal A conjugate vaccine in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Immunogenicity against serogroups A, C, W, and Y. Started Nov 2011; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2011-004421-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004421-27.